Verdict: Side-by-side breakdown using the Bull Rankings model. SRPT scored 19.4, ARGX scored 77.2 — ARGX leads.
Compare another set
Different reporting periods. SRPT's fundamentals are as of June 2026, but ARGX's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
SRPT
Sarepta Therapeutics, Inc.
Biotechnology · Quality-Growth
19.4
$17.85 · $1.9B
fundamentals as of
Score gap
57.8
ARGX leads
ARGX
argenx SE
Biotechnology · Quality-Growth
77.2
$825.03 · $51.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthARGX+89.9%
Strongest balance sheetARGX0.01
Highest qualityARGX72 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
SRPT
stronger →← stronger
ARGX
22
Qualityreturns · margins · balance sheet
72
15
Growthrevenue & earnings expansion
98
22
Valuevaluation vs sector peers
65
ARGX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
SRPT
ARGX
$82mC-
FCF
$679mC+
-20.4%F
Rev
+89.9%A
0.70C+
D/E
0.01A
1.0xA-
P/S
—
—
PEG
1.00B+
—
P/E
31.4xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
SRPT
ARGX
91% above
Price vs fair valuelower is cheaper
229% above
~15%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~47%/yr
-41%
1-yr DCF upside
-77%
-48%
5-yr DCF upside
-70%
-55%
10-yr DCF upside
-55%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
SRPT
Why this score
Diluting shareholders
ARGX
The companies
SRPTSarepta Therapeutics, Inc.
Biotechnology · $17.85 · beta 0.38
Why now
Biotechnology · market cap $1.9b. Down 28% from 52-week high of $24.68 — deep drawdown territory. Revenue -20% — in contraction; any catalyst that reverses this triggers re-rating. 22 sell-side analysts rate this a Hold with a mean 1-yr target of $21.64 (implying +21% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Revenue contracting -20% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -6.9%) — path to GAAP profitability is the core thesis risk. ROE -9% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
ARGXargenx SE
Biotechnology · $825.03 · beta -0.04
Why now
Biotechnology · market cap $51.9b. Down 23% from 52-week high of $1072.75 — deep drawdown territory. Revenue growing +90% — in hypergrowth territory. 23 sell-side analysts rate this a Buy with a mean 1-yr target of $1,154 (implying +40% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. $51.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 12.5x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where SRPT and ARGX diverge
On the headline score the gap is 57.8 points in favor of ARGX. The widest single difference is Growth, where ARGX leads by 83.0 points.
GrowthSRPT 15.0 · ARGX 98.0ARGX +83.0
QualitySRPT 22.2 · ARGX 72.1ARGX +49.9
ValueSRPT 21.9 · ARGX 65.1ARGX +43.2
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is ARGX or SRPT the better stock?
ARGX scores higher: ARGX 77.2, SRPT 19.4 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do ARGX and SRPT differ most?
The widest gap is growth, where ARGX leads by 83 points on the 0–100 pillar scale. ARGX leads all three pillars, so the gap is broad rather than a single-measure difference.
How are ARGX and SRPT scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.